Nicolas Noel
Overview
Explore the profile of Nicolas Noel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urbain F, Bicart-See L, Adam C, Adams D, Lambotte O, Labeyrie C, et al.
Rev Med Interne
. 2025 Mar;
PMID: 40068989
Neurolymphomatoses (NL) are defined as the direct infiltration of the peripheral nervous system (PNS) by lymphomatous or leukaemic cells. The diagnosis of this rare disease is complex, typically relying on...
2.
Urbain F, Labeyrie C, Castilla-Llorente C, Noel N, Farge D, Echaniz-Laguna A
Br J Haematol
. 2025 Mar;
206(3):996-999.
PMID: 40052451
No abstract available.
3.
Boschi G, Colle R, Noel N, Morin L, Chappell K, Pham T, et al.
J Psychiatr Res
. 2025 Feb;
183:106-111.
PMID: 39954540
Introduction: Although post-COVID major depressive disorder (MDD) is frequent, the physiological mechanisms associated with it remain unclear. This study aimed to assess the association between 10 residual blood markers of...
4.
Cottu A, Guillet S, Viallard J, Riviere E, Cheze S, Gobert D, et al.
Blood
. 2024 Oct;
145(2):244-247.
PMID: 39476101
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained...
5.
Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, et al.
NEJM Evid
. 2024 Oct;
3(11):EVIDoa2300354.
PMID: 39437137
Background: Cyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether infliximab is safer and more effective than cyclophosphamide in treating severe Behçet's syndrome is not known....
6.
Stammler R, Vacher L, Fournier B, Lemaire P, Chauvel C, Silvestrini M, et al.
J Med Virol
. 2024 Jul;
96(8):e29836.
PMID: 39078052
Primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma associated with Kaposi Sarcoma-associated herpesvirus (KSHV/HHV8) infection. Lymphoma cells are coinfected with Epstein-Barr virus (EBV) in 60-80% of cases. Tools...
7.
Pham T, Morin L, Savale L, Colle R, Figueiredo S, Harrois A, et al.
Respir Med Res
. 2024 Jun;
86:101099.
PMID: 38843604
Background And Objectives: Although many symptoms of post-COVID syndrome have been described, a comprehensive evaluation of their prevalence is lacking. We aimed to describe symptoms at 16 months from hospitalization...
8.
Cariou P, Pobel C, Michot J, Danlos F, Besse B, Carbonnel F, et al.
Eur J Cancer
. 2024 Apr;
204:114065.
PMID: 38643707
Background: Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data...
9.
Placais M, Laparra A, Maria A, Kramkimel N, Perret A, Manson G, et al.
Am J Hematol
. 2024 Apr;
99(7):1427-1430.
PMID: 38642007
No abstract available.
10.
de La Rochefoucauld J, Anguel N, Schmidt J, Noel N, Monnet X, Lambotte O
J Crit Care
. 2023 Dec;
80:154498.
PMID: 38104496
Secondary haemophagocytic lymphohistiocytosis (sHLH) proceeds from uncontrolled and inefficient immune activation leading to hyper-inflammation and multi-organ damage. sHLH proceeds from a wide panel of infectious, auto immune and malignant conditions...